Clindamycin-d3 (hydrochloride)

CAT:
804-HY-B1455S
Size:
1 mg

For Laboratory Research Only. Not for Clinical or Personal Use.

  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Clindamycin-d3 (hydrochloride) - image 1

Clindamycin-d3 (hydrochloride)

  • UNSPSC Description:

    Clindamycin-d3 (hydrochloride) is the deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria[1][2].
  • Target Antigen:

    Antibiotic; Bacterial; Parasite
  • Type:

    Isotope-Labeled Compounds
  • Related Pathways:

    Anti-infection
  • Field of Research:

    Infection
  • Purity:

    99.62
  • Solubility:

    10 mM in DMSO
  • Smiles:

    O=C([C@@H]1C[C@H](CN1C([2H])([2H])[2H])CCC)N[C@@H]([C@@]2([H])O[C@@H]([C@@H]([C@H]([C@H]2O)O)O)SC)[C@@H](Cl)C.Cl
  • Molecular Weight:

    464.46
  • References & Citations:

    [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Hodille E, et al. Clindamycin suppresses virulence expression in inducible clindamycin-resistant Staphylococcus aureus strains. Ann Clin Microbiol Antimicrob. 2018 Oct 20;17(1):38.
  • Shipping Conditions:

    Blue Ice
  • Storage Conditions:

    -20°C (Powder, sealed storage, away from moisture)
  • Clinical Information:

    No Development Reported
  • CAS Number:

    1356933-72-6